Grow your Business.
Optimize your time.

 About Profact

Description: ProFACT Proteomics, Inc. is an early-stage corporation founded in November 2004. The Company applies SeraFILE™ - its proprietary Functional Proteomics technology, to accelerate development of therapeutics and diagnostics, principally for cancer. ProFACT has a core executive team in place, scientific advisors, three pending patents and one licensed patent. Funding has come from four New Jersey Commission on Science and Technology (NJCST) grants, the US Therapeutic Tax Credit and internal sources. Service revenues from BioPharma and institutional clients have commenced.

SeraFileThe ProFACT team is highly experienced in developing and commercializing surface chemistries for biomolecule separations and sample preparation. Most of these chemistries have been adapted to consumable research products in partnership with Biotech Support Group LLC. Most notable are: Cleanascite™ for lipid adsorption, AlbuSorb™ & AlbuVoid™ for Albumin depletion, and HemogloBind™ & HemoVoid™ for Hemoglobin removal. These products have referenced in well over 100 technical journals with the largest commercial success being the incorporation of ProCipitate™ protocols into the Human Genome Sequencing Project. This separations experience in now being used in the development and application of a new surface library -SeraFILE™ for the subfractionation of proteomes into sub-proteomes with reduced complexity and functional characteristics retained for interrogations, producing a characterisitic profile of the sample.

Key Competitive Advantage: The SeraFILE™ deliverable is functional proteomic data, alone or adjunctive to conventional proteomic data. It has immediate value in the discovery, early validation and assay development of biomarkers. Furthermore, as significant conformational events accompany the binding of drugs, the need to generate molecular profiles that characterize the function of one or more gene products working coorperatively is a paramount consideration in drug development. As a result, ProFACT is uniquely positioned to build the bridge from proteomics data to drug discovery, drug repositioning, mechanism of action and personalized medicine.

Business Model: The company pursues a hybrid business model combining revenues from services with a risk capital investment plan. This will allow ProFACT to grow its biomarker and drug target intellectual property portfolio. The company evaluates in-licensing and out-licensing potential opportunistically and welcomes inquires in this regard. The Collaborations link on left describes several mechanisms to access technology. 

 Sample Preparation

ProFACT Proteomics and Biotech Support Group are in partnership to supply unique sample preparation and enrichment products into the systems biology research community. Please visit www.biotechsupportgroup.com for detailed product information and ordering.

© Copyright 2008 ProFACT Proteomics, Inc.

 Collaborations

DiscoverPrep™ | ProPrep™

Services | SeraFILE™ | Rational Genome to Proteome Prospecting™

SeraFILE™ | Rational Proteome Prospecting™ | Conformerics™ | Rational Genome to Proteome Prospecting™

ProFACT

Technologies

SeraFILE™

Rational Proteome Prospecting™

Conformerics™

Rational Genome to Proteome Prospecting™

Technologies

ProFACT offers a comprehensive suite of molecular profiling technologies readily integrated with other "omics" data for biomarker and drug target discovery. These include: SeraFILE™, for reduction of protein complexity and sub-proteome creation; Rational Proteome Prospecting™, to enrich and isolate functional activity; Conformerics™, to generate drug screening assays based on enzyme sub-states or conformers; and Rational Genome to Proteome Prospecting™, for prospecting into protein expression based on gene expression data.

In addition to the information contained on this website, these application specific documents can be downloaded by clicking the title:

Molecular Profiling With SeraFILE™

Poster Publication Prepared for Nature Methods, February 2008.

Abstract: The high throughput SeraFILE™ protocol generates biologically active sub-proteome pools with a lesser degree of complexity than the parent protein sample. Thus, dissecting the proteome prior to downstream analyses allows researchers to profile and study proteins in new ways. ProFACT's SeraFILE™ surface library affords high-resolution partitioning of complex protein extracts into differential sub-proteomes that can be further characterized using a variety of downstream applications.

Collectively, SeraFILE™-derived protein profiles offer a more comprehensive signature of the starting sample. SeraFILE™ can fractionate proteins and thus signatures may reveal discrete differences in low abundance proteins across samples. It is important to note that no high abundance proteins are removed from the sample prior to fractionation; they are distributed across sub-proteomes. Therefore, SeraFILE™ facilitates detection of disease-specific differences in clinical proteomics applications.

Reproducibility Of SeraFILE™ Derived Functional Proteomic Profiles

Prepared as an Application Report, April 2007.

Abstract: As sample heterogeneity causes normalization problems when characterizing across multiple samples, we describe here a validation of SeraFILE™ derived profile reproducibility within a broad protein variance window. In serum studies, it was experimentally determined that the amount of total protein can vary by up to 4X, while enzymatic activity profile patterns are consistently observed. This may be useful in tumor studies for example, where relative differences can still be interpreted, despite any disparities in the starting total tissue weight and/or total protein analyzed.

In addition, since protein and enzymatic activity profiles are reproducible over a range of protein application concentrations, the profiles may be used as predictors of sub-proteomes containing the highest enrichment of functional activities. Such predictive information may be useful for further prospecting and purification.

Functional Proteomic Signatures Of The Ubiquitin / Proteasome Pathway

Prepared as an Application Report, March 2007.

This report presents preliminary findings on the application of ProFACT's surface library - SeraFILE™, to the functional proteomic characterization of an important cellular pathway, the Ubiquitin/ Proteasome pathway (UPP). The results show:

Markedly contrasted signatures of matched cancer to normal adjacent tissue,

Differential pools of Proteasome regions and regulatory factors,

Altered catalytic rates, both higher and lower, on several different surfaces,

Evidence of conformational variants resistant to small molecule inhibitors,

Evidence of soluble regulatory factors that potentially could be isolated.

© Copyright 2008 ProFACT Proteomics, Inc.